Biopsy Devices Market Report 2026

Biopsy Devices Market Overview

• Biopsy Devices market size has reached to $3.24 billion in 2025 • Expected to grow to $4.95 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Surgical Demand Surge Fuels Growth In The Biopsy Devices Market • Market Trend: Olympus Unveils Secureflex To Elevate Precision And Tissue Quality In Fine Needle Biopsy Procedures • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biopsy Devices Market?

The biopsy devices are used to extract sample cells or tissues from the patient's body to be examined to determine the presence of a disease. They assist in diagnosing diseases, especially cancer, by enabling healthcare professionals to analyze cellular structures and identify abnormal or cancerous cells. The main product types in biopsy devices are needle-based biopsy instruments, core biopsy devices, aspiration biopsy needles, vacuum-assisted biopsy devices, biopsy forceps, and localization wires. The core biopsy devices utilize a large hollow needle to make a small incision in the skin over the lump. The various imaging technologies included are MRI-guided biopsy, stereotactic-guided biopsy, ultrasound-guided biopsy, and CT scan. The applications included in this market are breast biopsy, gynecological biopsy, prostate biopsy, liver biopsy, lung biopsy, kidney biopsy, gastroenterology biopsy, and others that are used in diagnostics and imaging centers, hospitals, and others.

What Is The Biopsy Devices Market Growth Forecast?

The biopsy devices market size is expected to see strong growth in the next few years. It will grow to $4.95 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing adoption of AI-assisted biopsy guidance, rising demand for outpatient diagnostic procedures, expansion of precision oncology practices, growing focus on early disease detection, increasing investments in advanced biopsy technologies. Major trends in the forecast period include increasing adoption of image-guided biopsy systems, rising use of minimally invasive biopsy techniques, growing demand for precision sampling devices, expansion of automated biopsy guidance technologies, enhanced focus on diagnostic accuracy.

Global Biopsy Devices Market Segmentation

1) By Product Type: Needle-Based Biopsy Guns, Biopsy Forceps, Biopsy Guidance Systems, Biopsy Needles, Other Products 2) By Image Guiding Technology: MRI-Guided Biopsy, Stereotactic-Guided Biopsy, Ultrasound-Guided Biopsy, Other Imaging Technologies 3) By Application: Breast Biopsy, Gynecological Biopsy, Prostate Biopsy, Blood Cancers Biopsy, Skin Biopsy, Kidney Biopsy, Gastroenterology Biopsy, Other Applications 4) By End User: Diagnostics And Imaging Centers, Hospitals, Other End User Subsegments: 1) By Needle-Based Biopsy Guns: Spring-Loaded Biopsy Guns, Vacuum-Assisted Biopsy Guns 2) By Biopsy Forceps: Endoscopic Biopsy Forceps, Surgical Biopsy Forceps 3) By Biopsy Guidance Systems: Ultrasound-Guided Biopsy Systems, CT-Guided Biopsy Systems, MRI-Guided Biopsy Systems 4) By Biopsy Needles: Core Needles, Fine Needle Aspiration (FNA) Needles, Coaxial Needles 5) By Other Products: Biopsy Sutures, Biopsy Markers, Biopsy Storage Solutions

What Is The Driver Of The Biopsy Devices Market?

A growing number of surgeries is expected to propel the growth of the biopsy devices market. Surgery is a medical discipline focused on addressing injuries, illnesses, and various disorders through the application of both manual and instrumental methods. In surgical procedures, biopsy devices are frequently employed to extract a small tissue sample or a collection of cells for subsequent laboratory analysis. For instance, in July 2025, according to the American Med Spa Association, a US-based provider of legal, compliance, and business resources for medical spas and medical aesthetic practices, cosmetic procedure volumes have risen by 42.5% over the past four years, reaching 20.5 million non-surgical treatments and 17.4 million surgical procedures in 2024. Therefore, the growing number of surgeries is driving the growth of the biopsy devices industry going forward.

Key Players In The Global Biopsy Devices Market

Major companies operating in the biopsy devices market are Becton Dickinson and Company, Hologic Inc, Boston Scientific Corporation, Cook Medical LLC, Argon Medical Devices Inc, Olympus Corporation, Medtronic plc, Stryker Corporation, B Braun Melsungen AG, INRAD Inc, TSK Laboratory, Mauna Kea Technologies, Veran Medical Technologies, Merit Medical Systems Inc, ConMed Corporation, DTR Medical, Gallini Srl, TransMed7 LLC, MDL Srl, Biopsybell Srl

Global Biopsy Devices Market Trends and Insights

Major companies operating in the biopsy devices market are focusing on developing advanced solutions such as fine-needle biopsy precision technology to enhance diagnostic accuracy and sample quality. Fine-needle biopsy precision technology refers to the design of needles with specialized tips and durable materials that improve tissue extraction while preserving cell architecture, thereby supporting reliable pathology analysis. For instance, in October 2025, Olympus, a Japan-based medical-technology company, launched its SecureFlex single-use fine-needle biopsy device featuring nitinol construction and a dual-beveled Raptor Tip. This tip supports the collection of larger, intact tissue specimens by minimizing tissue escape and improving puncture performance. The construction includes a multi-layer sheath that enables consistent access to complex anatomical structures such as the pancreatic head and uncinate process without frequent scope adjustments. SecureFlex supports fine-needle biopsy via EUS-FNB for gastrointestinal lesions and allows physicians to obtain high-quality tissue for precise diagnosis and treatment planning. The device contributes to better sample quality, procedural efficiency, and safety in endoscopic biopsy procedures.

What Are Latest Mergers And Acquisitions In The Biopsy Devices Market?

In June 2023, Quest Diagnostics, a US-based medical laboratories company, acquired Haystack Oncology for an undisclosed amount. Quest Diagnostics plans to integrate the MRD technology of Haystack Oncology into the creation of novel blood-based clinical laboratory services for solid tumor cancers, with availability scheduled to commence in 2024. Haystack Oncology is a US-based company that has developed a highly sensitive minimal-residual disease (MRD) testing technology based on circulating tumor DNA (ctDNA).

Regional Outlook

North America was the largest region in the biopsy devices market in 2025. Asia-Pacific was the second largest region in the global biopsy devices market report share. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Biopsy Devices Market?

The biopsy devices market consists of sales of core biopsy guns, core biopsy needles, aspiration biopsy needles, vacuum-assisted biopsy systems, vacuum-assisted biopsy needles, localization wires, procedure trays, and other biopsy devices that are used to diagnose various diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.